Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer: Treatment outcome outside clinical trials

Strahlentherapie und Onkologie

Volumn 188, Issue 5, 2012, Pages 377-382

  Winkler, J ^a   Zipp, L ^a   Knoblich, J ^b   Zimmermann, F ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Outpatient Oncology Centre   (Germany)

Author keywords

Capecitabine; Oxaliplatin; Rectal cancer; Toxicity

Indexed keywords

CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PLATINUM COMPLEX;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT; CANCER CONTROL; CANCER GROWTH; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG SAFETY; DYSESTHESIA; DYSURIA; ELECTROLYTE DISTURBANCE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MALE; NAUSEA; PAIN; PARESTHESIA; PERIANAL PAIN; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PROCTITIS; RADIATION DOSE; RASH; RECTUM CANCER; SIDE EFFECT; SKIN TOXICITY; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR REGRESSION; VAGINA MYCOSIS; ADENOCARCINOMA; ADJUVANT THERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECTUM TUMOR; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862663966     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0073-8     Document Type: Article

References (46)

1. Ang C, Kornbluth M, Thirlwell MP et al (2010) Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol 17:59-63
2. Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773-2780
3. Basso M, Cassano A, Modoni A et al (2008) A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur J Clin Pharmacol 64:739-741
4. Bekelman JE, Shah A, Hahn SM (2011) Implications of comparative effectiveness research for radiation oncology. Pract Radiat Oncol 1:72-80
5. Bonnen M, Crane C, Vauthey JN et al (2004) Longterm results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys 60:1098-1105 (Pubitemid 39440794)
6. Boulis-Wassif S, Gerard A, Loygue J et al (1984) Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 53:1811-1818 (Pubitemid 14127631)
7. Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687-3694
8. Cassidy J, Clarke S, Diaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012
9. Chua YJ, Barbachano Y, Cunningham D et al (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11:241-248
10. Cividalli A, Ceciarelli F, Livdi E et al (2002) Radio-sensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52:1092-1098 (Pubitemid 34219031)
11. Gramont A de, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947 (Pubitemid 30644117)
12. De Paoli A, Chiara S, Luppi G et al (2006) Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 17:246-251 (Pubitemid 43160113)
13. Dunst J, Debus J, Rudat V et al (2008) Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol 184:450-456
14. Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19-23 (Pubitemid 27138353)
15. Eich HT, Stepien A, Zimmermann C et al (2011) Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression. Strahlenther Onkol 187:225-230
16. Fels F, Kraft JW, Grabenbauer GG (2010) Geriatrics and radiation oncology. Part 1: How to identify high-risk patients and basic treatment principles. Strahlenther Onkol 186:411-422
17. Fernandez-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 28:859-865
18. Freeman NJ, Costanza ME (1988) 5-Fluorouracil-associated cardiotoxicity. Cancer 61:36-45
19. Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638-1644
20. Gerard JP, Chapet O, Nemoz C et al (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21:1119-1124 (Pubitemid 46594142)
21. Glynne-Jones R, Sebag-Montefiore D, Maughan TS et al (2006) A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 17:50-56 (Pubitemid 43033839)
22. Guillem JG, Diaz-Gonzalez JA, Minsky BD et al (2008) cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 26:368-373 (Pubitemid 351171686)
23. Habr-Gama A, Perez RO, Sabbaga J et al (2009) Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 52:1927-1934
24. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292 (Pubitemid 32366981)
25. Kim DY, Jung KH, Kim TH et al (2007) Comparison of 5-fluorouracil/ leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 67:378-384 (Pubitemid 46108315)
26. Koeberle D, Burkhard R, Moos R von et al (2008) Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98:1204-1209 (Pubitemid 351481682)
27. Kosmas C, Kallistratos MS, Kopterides P et al (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134:75-82 (Pubitemid 350060687)
28. Kuchenmeister U, Kirchner R, Mellert J et al (2000) First results of neoadjuvant simultaneious radiochemotherapy in advanced rectal carcinoma. Strahlenther Onkol 176:560-566
29. Machiels JP, Duck L, Honhon B et al (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 16:1898-1905 (Pubitemid 41724278)
30. Marquardt F, Rodel F, Capalbo G et al (2009) Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 185:371-378
31. Ng M, Cunningham D, Norman AR (2005) The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 41:1542-1546 (Pubitemid 40981835)
32. Ofner D, Devries AF, Schaberl-Moser R et al (2011) Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary pperable, cT(3)NxM0, low rectal cancer: a Phase II study. Strahlenther Onkol 187(2):100-107
33. Rodel C, Arnold D, Becker H et al (2010) Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer: is it time for a randomized phase III trial? Strahlenther Onkol 186:658-664
34. Rodel C, Fietkau R, Keilholz L et al (1997) The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma. Strahlenther Onkol 173:415-421 (Pubitemid 27360192)
35. Rodel C, Grabenbauer GG, Papadopoulos T et al (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098-3104 (Pubitemid 46613485)
36. Rodel C, Liersch T, Hermann RM et al (2007) Multi-center phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110-117 (Pubitemid 350003058)
37. Rodel C, Sauer R (2007) Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 183:227-235 (Pubitemid 46725993)
38. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740
39. Sawada N, Ishikawa T, Sekiguchi F et al (1999) Xray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5:2948-2953 (Pubitemid 29493974)
40. Schmiegel W, Pox C, Reinacher-Schick A et al (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 48:65-136
41. Trotti A, Byhardt R, Stetz J et al (2000) Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47 (Pubitemid 30179675)
42. Van Cutsem E, Hoff PM, Blum JL et al (2002) Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 13:484-485 (Pubitemid 34705014)
43. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106 (Pubitemid 33049527)
44. Wolff HA, Gaedcke J, Jung K et al (2010) High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer. Strahlenther Onkol 186:30-35
45. Wolff HA, Hennies S, Herrmann MK et al (2011) Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer. Strahlenther Onkol 187:52-58
46. http://www.clinicaltrials.gov, accessed 23 February 2012